$9.78
0.62% yesterday
NYSE, Oct 15, 10:00 pm CET
ISIN
US03168L1052
Symbol
AMRX

Amneal Pharmaceuticals, Inc. Class A Stock price

$9.78
-0.01 0.10% 1M
+2.61 36.40% 6M
+1.86 23.48% YTD
+0.97 11.01% 1Y
+7.72 374.76% 3Y
+4.74 94.05% 5Y
-28.18 74.24% 10Y
+5.11 109.42% 20Y
NYSE, Closing price Wed, Oct 15 2025
+0.06 0.62%
ISIN
US03168L1052
Symbol
AMRX
Industry

Key metrics

Basic
Market capitalization
$3.1b
Enterprise Value
$5.5b
Net debt
$2.5b
Cash
$71.5m
Shares outstanding
314.0m
Valuation (TTM | estimate)
P/E
972.0 | 12.4
P/S
1.1 | 1.0
EV/Sales
1.9 | 1.8
EV/FCF
21.1
P/B
negative
Financial Health
Equity Ratio
-3.1%
Return on Equity
107.0%
ROCE
16.4%
ROIC
9.2%
Debt/Equity
-22.5
Financials (TTM | estimate)
Revenue
$2.9b | $3.1b
EBITDA
$625.2m | $691.1m
EBIT
$379.8m | $574.2m
Net Income
$3.4m | $245.9m
Free Cash Flow
$261.6m
Growth (TTM | estimate)
Revenue
47.2% | 9.6%
EBITDA
40.9% | 18.2%
EBIT
73.9% | 64.8%
Net Income
104.1% | 310.3%
Free Cash Flow
48.6%
Margin (TTM | estimate)
Gross
37.7%
EBITDA
21.9% | 22.6%
EBIT
13.3%
Net
0.1% | 8.0%
Free Cash Flow
9.2%
More
EPS
$0.0
FCF per Share
$0.8
Short interest
2.8%
Employees
8k
Rev per Employee
$340.0k
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
90%
Hold
10%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,853 2,853
47% 47%
100%
- Direct Costs 1,778 1,778
40% 40%
62%
1,075 1,075
60% 60%
38%
- Selling and Administrative Expenses 498 498
46% 46%
17%
- Research and Development Expense 203 203
65% 65%
7%
625 625
41% 41%
22%
- Depreciation and Amortization 245 245
9% 9%
9%
EBIT (Operating Income) EBIT 380 380
74% 74%
13%
Net Profit 3.38 3.38
104% 104%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Positive
MarketBeat
13 days ago
The global healthcare market is growing rapidly—it is expected to climb at a 6.9% CAGR over the next eight years, reaching more than $22.3 trillion by 2033. Its appeal to investors in the current market environment may also lie in its non-cyclical nature, thanks to resilient demand that is more related to health needs and demographics than to external economic conditions.
Neutral
GlobeNewsWire
15 days ago
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
Neutral
GlobeNewsWire
19 days ago
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 8,300
Founded 2002
Website amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today